Episode Details

The 80%: Core Clinical Guidelines & Actionable Insights

• Role: Intermediate-acting, nondepolarizing neuromuscular blocker (NMBA) for routine/RSI intubation, surgery, or mechanical ventilation.
• Mechanism: Competes with acetylcholine at motor end-plates. Paralysis moves from fine muscles (face/neck) to limbs, chest, abdomen, and diaphragm; recovery is in reverse. A vecuronium analog with 10–15% potency, it was developed to match succinylcholine's onset. Minimal histamine release/ganglion blockade makes bronchospasm, hypotension, or heart rate shifts rare.
• Crucial Administration:
  • Rules: Give only after unconsciousness is induced with sedation, analgesia, and amnesia. Ventilatory support is mandatory. Do not mix with alkaline solutions (e.g., thiopental) due to acidic pH.
  • Monitoring/Route: Direct IV over 5–10s; monitor with nerve stimulators (target 1–2 twitches). Infusions dilute up to 5 mg/mL (or 10 mg/mL undiluted). IM use is non-FDA-approved and discouraged (slow/inconsistent).
• Dosing Guidelines:
  • Routine: Adults: 0.45–1.2 mg/kg (onset <2m); Pediatrics: 0.45–0.6 mg/kg (onset 60–75s); Neonates: 0.45–0.6 mg/kg (onset 1–2m).
  • RSI: Adults: 0.6–1.2 mg/kg (onset <2m); Pediatrics: 0.6–1.2 mg/kg (usual: 1 mg/kg, onset 1–2 minutes); Neonates: 0.45–1.2 mg/kg.
  • ICU Vent: Adults: 0.6–1 mg/kg bolus, then 0.1–1 mg/kg prn or 8–12 mcg/kg/min; Pediatrics/Neonates: 0.6 mg/kg bolus, then 5–10 mcg/kg/min.
  • Surgery: Infusions: 10–12 mcg/kg/min (adults); 7–12 mcg/kg/min (pediatrics).

The 20%: Pharmacokinetics, Special Populations, & Risks

• Pharmacokinetics: Extracellular distribution (not fat), ~30% protein bound. Tissue redistribution accounts for 80% of initial dose; maintenance infusion falls to ~20% of initial rate in 4–8 hours as tissues fill. CYP3A4 metabolizes it to an active form with 1/20th potency. Half-life: neonates (1.1h), older children (0.7–0.8h), adults (1.4–2.4h). Bolus duration: 22–67 min.
• Special Populations:
  • Hepatic: Hepatic dysfunction prolongs recovery; ascites may require larger initial doses.
  • Renal: Renal failure causes highly variable duration.
  • Lactation: Poor lipid solubility and oral absorption make infant exposure unlikely (breastfeeding can resume 90m–5h post-anesthesia).
• Adverse & Storage: Severe risks: bronchospasm, anaphylaxis, angioedema, malignant hyperthermia, acute myopathy, thrombosis. Shortage update: FDA allows emergency extended vial use up to 2h at room temp or 4h refrigerated.